InsiderTrades.com logo

Preston Klassen Biography and Net Worth

Insider of Regulus Therapeutics
  • Phone
  • Email
  • Website


Preston Klassen joined Regulus in 2023 and serves as president and head of research and development. He joined Regulus from Metacrine where he served as president and chief executive officer. From June 2016 to March 2017, he was chief medical officer of Laboratoris Sanifit S.L., and prior to that, was executive vice president, head of global development at Orexigen Therapeutics, Inc. Dr. Klassen also held several positions of increasing responsibility at Amgen Inc., including therapeutic area head for nephrology. Before joining Amgen, he was a faculty member in the Division of Nephrology at Duke University Medical Center. Dr. Klassen has previously served on the board of Conatus Pharmaceuticals, Corvidia Therapeutics and Chinook Therapeutics. He holds a B.S. in chemistry from Central University of Iowa. Dr. Klassen received his medical degree from the University of Nebraska College of Medicine and completed his residency in internal medicine, fellowship in nephrology, and Master of Health Sciences degree at Duke University.

What is Preston Klassen's net worth?

The estimated net worth of Preston Klassen is at least $392.13 thousand as of June 3rd, 2025. Dr. Klassen owns 48,055 shares of Regulus Therapeutics stock worth more than $392,129 as of December 5th. This net worth evaluation does not reflect any other assets that Dr. Klassen may own. Learn More about Preston Klassen's net worth.

How old is Preston Klassen?

Dr. Klassen is currently 55 years old. There are 3 older executives and no younger executives at Regulus Therapeutics. The oldest executive at Regulus Therapeutics is Mr. Christopher Ray Aker J.D., Senior VP, General Counsel & Corporate Secretary, who is 63 years old. Learn More on Preston Klassen's age.

How do I contact Preston Klassen?

The corporate mailing address for Dr. Klassen and other Regulus Therapeutics executives is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. Regulus Therapeutics can also be reached via phone at (858) 202-6300 and via email at [email protected]. Learn More on Preston Klassen's contact information.

Has Preston Klassen been buying or selling shares of Regulus Therapeutics?

Preston Klassen has not been actively trading shares of Regulus Therapeutics in the last ninety days. Most recently, on Tuesday, June 3rd, Preston Klassen bought 12,000 shares of Regulus Therapeutics stock. The stock was acquired at an average cost of $7.99 per share, with a total value of $95,880.00. Following the completion of the transaction, the insider now directly owns 48,055 shares of the company's stock, valued at $383,959.45. Learn More on Preston Klassen's trading history.

Who are Regulus Therapeutics' active insiders?

Regulus Therapeutics' insider roster includes Christopher Aker (VP), David Baltimore (Director), Crispina Calsada (CFO), Kathryn Collier (Director), Denis Drygin (Insider), Joseph Hagan (CEO), and Preston Klassen (Insider). Learn More on Regulus Therapeutics' active insiders.

Are insiders buying or selling shares of Regulus Therapeutics?

During the last twelve months, Regulus Therapeutics insiders bought shares 3 times. They purchased a total of 81,610 shares worth more than $171,166.60. During the last twelve months, insiders at the biopharmaceutical company sold shares 4 times. They sold a total of 223,998 shares worth more than $282,237.48. The most recent insider tranaction occured on June, 3rd when insider Preston Klassen bought 12,000 shares worth more than $95,880.00. Insiders at Regulus Therapeutics own 4.4% of the company. Learn More about insider trades at Regulus Therapeutics.

Information on this page was last updated on 6/3/2025.

Preston Klassen Insider Trading History at Regulus Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/3/2025Buy12,000$7.99$95,880.0048,055View SEC Filing Icon  
1/13/2025Sell31,445$1.26$39,620.7036,055View SEC Filing Icon  
See Full Table

Preston Klassen Buying and Selling Activity at Regulus Therapeutics

This chart shows Preston Klassen's buying and selling at Regulus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Regulus Therapeutics Company Overview

Regulus Therapeutics logo
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $8.16
Low: $8.16
High: $8.16

50 Day Range

MA: $8.10
Low: $7.87
High: $8.30

2 Week Range

Now: $8.16
Low: $0.83
High: $8.35

Volume

N/A

Average Volume

1,018,158 shs

Market Capitalization

$564.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.35